Outlook on the Digital Diabetes Management Global Market to 2027 - Featuring Abbott Laboratories, Bayer & Dexcom Among Others - ResearchAndMarkets.com

The "Digital Diabetes Management - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Digital Diabetes Management estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$22.1 Billion by 2027, growing at a CAGR of 18.5% over the analysis period 2020-2027.

Devices, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$13.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Application segment is readjusted to a revised 20.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 23.4% CAGR

The Digital Diabetes Management market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2027 trailing a CAGR of 23.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.4% and 17% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.9% CAGR.

Data Management Software & Platforms Segment to Record 16.8% CAGR

In the global Data Management Software & Platforms segment, USA, Canada, Japan, China and Europe will drive the 16.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$545.6 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.2 Billion by the year 2027, while Latin America will expand at a 18.1% CAGR through the analysis period.

Select Competitors (Total 35 Featured):

  • Abbott Laboratories
  • ACON Laboratories
  • Agamatrix, Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Dariohealth Corporatio
  • Dexcom, Inc.
  • F. Hoffmann-La Roche
  • Glooko, Inc.
  • Insulet Corporation
  • Johnson and Johnson
  • Lifescan, Inc.
  • Medtronic PLC
  • Novo Nordisk A/S
  • Tandem Diabetes Care, Inc.
  • Terumo corporation
  • Tidepool

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • AUSTRALIA
  • INDIA
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA

IV. COMPETITION

  • Total Companies Profiled: 35

For more information about this report visit https://www.researchandmarkets.com/r/8v6miq

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.